Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Small trial shows daclizumab add-on therapy improves MS outcome

25.05.2004


A small clinical trial of patients with multiple sclerosis (MS) who did not respond to interferon alone found that adding the human antibody daclizumab improved patient outcome. Patients who received the combined therapy had a 78 percent reduction in new brain lesions and a 70 percent reduction in total lesions, along with other significant clinical improvements. The trial was led by investigators at the National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health. Findings will appear in the Early Edition of the Proceedings of the National Academy of Sciences1 the week of May 24-28, 2004.



MS is a chronic disease marked by inflammation in the central nervous system and development of lesions in the brain. Messages from the brain to the body are interrupted as nerve fibers begin to lose their protective coating of myelin, resulting in muscle weakness, problems with vision and coordination, pain, and, in some patients, cognitive impairments. Approximately 250,000 to 350,000 people in the United States suffer from MS and about 200 new cases are diagnosed by physicians each week. There is no cure for the disorder.

NINDS investigator Roland Martin, M.D., and colleagues studied 11 patients with either relapsing-remitting2 or secondary progressive3 MS. Each patient was treated with beta interferon - a naturally occurring antiviral protein commonly used to treat MS. Patients also received 7 treatments of daclizumab (a genetically engineered human antibody that blocks the interleukin-2 receptor on immune cells) administered intravenously at 2-week, and later, 4-week intervals.


Ten patients showed a reduction in both the severity and number of brain lesions as demonstrated by magnetic resonance imaging. The decrease in new lesions, as well as the total decrease in lesions, occurred gradually over a 2-month span. Improvement was also seen on a neurological rating scale and in a test of hand function. The clinical improvement was unexpected in such a small trial, since a larger number of patients is usually required to show clinical effects. One patient with extremely high inflammation activity responded initially to daclizumab but, as disease activity returned, was given higher doses of the antibody and was excluded from final analysis.

"There is great interest now in new approaches and new therapies for a disorder about which we know too little and have only moderately effective therapies," said Dr. Martin. "The combined therapy was well tolerated by all patients, with side effects that were either mild or clearly not caused by daclizumab." He said the therapy limits the activity of T-cells that attack the myelin coating around the nerves, without shutting down the entire immune system.

"While these results are preliminary, this discovery offers hope for thousands of patients with certain forms of MS. Findings like this are helping us to better understand how this disease affects the immune system, which offers hope for all MS patients," said Story C. Landis, Ph.D., NINDS director.

Further studies are needed to confirm the extent of the clinical benefit of daclizumab on typical MS patients and determine whether daclizumab is effective as a stand-alone therapy.

The study was a collaboration between the NINDS and its sister agency, the National Cancer Institute (NCI). Thomas Waldmann, M.D., chief of the metabolism branch for NCI’s Center for Cancer Research, developed the antibody used in the trial.

Daclizumab (trade name Zenapax®) received FDA approval in 1997 for use in kidney transplantation.


The NINDS is a component of the National Institutes of Health within the Department of Health and Human Services and is the nation’s primary supporter of biomedical research on the brain and nervous system.

1 Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Wirfel J, Ohayon J, Waldmann TA, McFarland HF, and Martin R. "Humanized Anti-CD25 (Daclizumab) Inhibits Disease Activity in Multiple Sclerosis Patients Failing to Respond to Interferon-beta." Proceedings of the National Academy of Sciences, Vol. 101, Issue 23, pp. 8705-8708.
2 A course of MS in which some patients experience a series of attacks followed by complete or partial remission of symptoms that return after a period of stability.
3 MS that may begin with a relapsing-remitting course, followed by gradual clinical decline with no distinct remissions.

Paul Girolami | NINDS
Further information:
http://www.ninds.nih.gov/news_and_events/pressrelease_ms_daclizumab_052404.htm?type=current

More articles from Health and Medicine:

nachricht A 'half-hearted' solution to one-sided heart failure
24.11.2017 | Boston Children's Hospital

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New proton record: Researchers measure magnetic moment with greatest possible precision

High-precision measurement of the g-factor eleven times more precise than before / Results indicate a strong similarity between protons and antiprotons

The magnetic moment of an individual proton is inconceivably small, but can still be quantified. The basis for undertaking this measurement was laid over ten...

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

IceCube experiment finds Earth can block high-energy particles from nuclear reactions

24.11.2017 | Physics and Astronomy

A 'half-hearted' solution to one-sided heart failure

24.11.2017 | Health and Medicine

Heidelberg Researchers Study Unique Underwater Stalactites

24.11.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>